Reader response: Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?
DavidBaker, Professor, Queen Mary University of London
Submitted June 28, 2020
Maarouf et al.1 findings on rituximab support the results found with ocrelizumab,2 and they indicate, further, the value of an extended dose interval—above the standard monthly dosing over 6 months—can be found with CD20-depleting antibodies.
Maarouf A, Rico A, Boutiere C, et al. Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond? Neurol Neuroimmunol Neuroinflamm 2020;7:e825.
Baker D, Pryce G, James LK, Marta M, Schmierer K. The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis. Mult Scler Relat Disord 2020;44:102279.
Maarouf et al.1 findings on rituximab support the results found with ocrelizumab,2 and they indicate, further, the value of an extended dose interval—above the standard monthly dosing over 6 months—can be found with CD20-depleting antibodies.
Disclosure
For disclosures, please contact the editorial office at journal@neurology.org.
Reference